Supernus Pharmaceuticals, Inc.
SUPN
$48.27
$1.122.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 5.47% | -1.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.47% | -1.83% | |||
| Cost of Revenue | 0.48% | 23.60% | |||
| Gross Profit | 7.63% | -9.87% | |||
| SG&A Expenses | 7.39% | 1.80% | |||
| Depreciation & Amortization | -1.21% | 4.56% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.35% | 7.68% | |||
| Operating Income | 26.84% | -163.20% | |||
| Income Before Tax | -868.87% | -210.87% | |||
| Income Tax Expenses | 119.77% | -266.91% | |||
| Earnings from Continuing Operations | -2,445.62% | 44.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2,445.62% | 44.14% | |||
| EBIT | 26.84% | -163.20% | |||
| EBITDA | 8.62% | -49.19% | |||
| EPS Basic | -2,425.63% | 44.41% | |||
| Normalized Basic EPS | -0.73% | -135.33% | |||
| EPS Diluted | -2,425.00% | 44.67% | |||
| Normalized Diluted EPS | -0.73% | -135.33% | |||
| Average Basic Shares Outstanding | 0.73% | 0.53% | |||
| Average Diluted Shares Outstanding | 0.73% | 0.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||